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Diastoiic dysfunction is an important cause of symptoms h 
patients with various types of cardiic disease. Increased left 
ventricular diastolic pressure may lead to pulmonary congestion, 
even in the setting of normal Left ventricuiar systolic function. 
Although the pbysiotogy of diastolic function is complex, left 
ventricular diastolic pressure may become elevated througb one of 
three broad mechanisms. Abnormalities intrinsic to the Iefi ven- 
tricle may inciude 1) impaired left ventricular relaxation, a iindhtg 
that is common i  most cardiac diseases and may be particubwty 
hnportant during ischemia; 2) increased left ventrkxdar wafi 
thkkness relative to cavity volume, which will shift the diastolic 
pressuse-volume relation such that the same vohune is associated 
with a higher pressure; and 3) increased myocardial stiffness, 
which is thought to be associated with htterstitial fibrosis or scar 
The function of the heart is twofold: 1) to receive blood in 
diastole under low pressure, and 2) to eject blood into the 
great vessels in amounts commensurate with the metabolic 
requirements of the body. Heart failure may thus be defined 
as an inadequacy of either function. In recent years, there 
has been growing appreciation f the importance of diastolic 
dysfunction i  causing symptoms of congestive symptoms 
(l-3). For the purposes of this review, we will use the term 
“heart failure” to refer to symptoms referable to either 
pulmonary congestion due to elevated left ventricular dia- 
stoiic pressure or symptoms related to low cardiac output. 
Hemodynamic variables that reflect left ventricular dia- 
stolic function (for example, pulmonary capillary wedge 
pressure at rest) correlate more closely with exercise toler- 
ance than does the left ventricular ejection fraction in 
patients with heart failure (3). Right ventricular ejection 
fraction also has been found to be a good predictor of 
exercise capacity, perhaps because right ventricular ejection 
phase indexes reflect right ventricular afterload. which is 
determined at least in part by mean pulmonary capillary 
wedge pressure (3). In a subgroup of patients, heart failure 
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tissue formation. In addition, diastolic presflw~ may became 
elevated became offactors exbhsic t0 the left ~e~~tricle. These 
may h&de 1) increased central blood v&me, whkdt will ht. 
crease k4? ventrlenlar pressare without altering the left ~e~tricu. 
lar pressure4vdutne relation; and 2) ventriculer interaction me- 
diated by perirardkd restraint, which may cause a puraket 
Upward Sbft Of the dh3tOlk pK.BUre-vUlume r&&m. lk&m& 
Of the f&tOrS extrinsic tothe left ventricle t nds to be much mere 
suceessFul than treating abnonnatities that are intrh& to the 
veittrfcfe. fn&Woved uuderstandhtg of myocardDf relax&on at the 
ceikdar level and delineation of the molecular regdation of 
myocyte hypertrophy and fibroblast proliferation may lead to uew 
and innovative approaches to the treatment ofheart failure. 
(J Am Cd Cad01 1993;22[Sugp&meus A].#A-SSAJ 
may be due exclusively to diastolic dysfunction (4). How- 
ever, the majority of patients with heart failure have both 
systolic and diastolic dysfunction. Because systole and 
diastole are intricately and inextricably inked, it may be 
dilkult to separate the effects of altered systolic and dia- 
stolic function in an individual patient. The distinction is 
important because therapeutic goals may be quite different 
depending on the predominant abnormality. In this report, 
we will first review the physiology of normal diastolic 
function and subsequently discuss the alterations that com- 
monly occur in different cardiac diseases. We will then 
examine the rationale for different ypes of interventions 
intended to improve diastolic dysfunction. 
Normal Physiology 
In the normal heart, diastolic filling is modulated by the 
complex interaction f many variables (5). Diastolic lilling of 
the l& ventricle isgenerally a biphasic process, with passive 
(rapid) 6lling in early diastole and active filling due to atrial 
contraction i late diastole. Tnerefore, it is helpful to con- 
sider separately the factors that affect early diastole predom- 
inantly and those that are more Important inlate diitole. 
!%I$ diastolic filling of the left ventricle occurs when left 
at& l.ucssure exceeds left ventricuh-ir pressure. This CTOSS- 
over pressure isdetermined by both left atrial pressure and 
the rate of left ventricular relaxation. Left ventricular relax- 
ation proceeds as free ionized calcium is released from its 
binding site OQ tioponin C, allowing the actin-myosin Cmss- 
bridges to dissociate (6,7). The amount of calcium bound to 
the myofflaments at any given point in time depends on the 
073%1097ws6.00 
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anity of troponin C for calcium and the concentration f 
free calcium in the cytoplasm. Cytoplasmic calcium concen- 
tration, in turn, is regulated by the rate of calcium reuptake 
into the sarcoplasmic reticulum and extrusion of calcium 
from the cell by the sanzolemmal sodium-calcium exchanger 
and a sarcolemmal calcium pump (6,7). Transportation f 
calcium into the sarcoplasmic reticulum occurs against a 
large concentration gradient and thus requires energy that is 
liberated when hii energy phosphates are split by an 
enzyme, adenosine triphosphatase, that is closely associated 
with the sarcoplasmic reticuhun. Sarcoplasmic reticular se- 
questration f calcium is modulated by enzymatic modifica- 
tion of a protein, phospholamban, that is associated with the 
sarcoplasmic reticular adenosine triphosphatase. Under 
normal conditions, phospholamban inhibits sarcoplasmic 
reticular adenosine triphosphatase activity and thus slows 
calcium uptake. Production of cyclic adenosine monophos- 
phate (AMP) in the myocyte promotes phosphorylation f 
phospholamban through the actions of a cyclic AMP- 
dependent protein kinase. The tonic inhibition of sarcoplas- 
mic reticular adenosine triphosphatase activity is released 
when phospholamban is phosphorylated. 
Late diastolic filling of the left ventricle coincides with 
atrial contrac&~n (when sinus rhythm is present). The extent 
of late diastolic filling is determined in part by atria1 contrac- 
tility, left atrial pressure and left ventricular operating cham- 
ber stiffness (the slope of the diastolic pressure-volume 
relation). The overall chamber stiffness is strongly influ- 
enced by the geometry ofthe ventricle. Chamber stiffness i
directly proportional tothe ratio of wall volume to cavity 
volume. In addition, chamber stiffness also reflects the 
resistance todeformation f an individual unit of myocar- 
dium (myoctiial stiffness) (8). Based on the preceding 
relation, increased left ventricular wall thickness relative to 
cavity dimensions (as seen in concentric left ventricular 
hypertrophy) or increased myocardial stiffness (due to inter- 
stitial fibrosis) will tend to increase chamber stitfness. Like- 
wise, increased filling pressures will cause the ventricle to 
operate on a steeper (stiffer) portion of the pressure-volume 
relation (Fig. 1). 
Both early and late filling are strongly influenced by left 
ventricular loading conditions. In patients with no evidence 
of cardiac disease, both peak early filling velocity and early 
filling fraction decrease aspreload isdecreased (for example, 
after intravenous nitroglycerin), and both increase as pre- 
load is increased (for example, after fluid administration). 
These actions illustrate the fact that at any given point in 
time some variables of diastolic filling cannot be equated 
directly with “diastolic function” because they are depen- 
dent on factors extrinsic to the ventricle (9). 
A major limitation i  the study of diastole has been the 
Paucity of uniformly accepted variables that define diastoiic 
function. No individual measurement can fully characterize 
all of the different aspects of diastolic function, nor is any 
One measurement free of complicating factors (IO). Further- 
more, many of the variables used have been obtained using 
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Ftgure 1. Graphic diagrams of ventricular pressure-volume rela- 
tions in heart failure. Upper panel, Normal pressure-volume relation 
illustrating depression fthe end-systolic pressure-volume relation 
when congestive heart failure (CHF) is due solely to systolic 
dysfunction. Middle panel, Pure diastolic dysfunction. This type of 
abnormality would cause elevation of diastolic pressure and pulmo- 
nary congestion. The end-systolic pressure-volume relation is pre- 
served, whereas the diastolic ventricular p essure-volume relation is
shifted upward. Lower panel, Mixed systolic and diastolic dysfunc- 
tion, a common scenario that would lead to symptoms of heart 
failure due to pulmonary congestion a d low output. Adapted, with 
permission f the American Heart Association, Inc., from Gross- 
man (2). 
sophisticated invasive procedures. Therefore, their applica- 
bility in the routine clinical setting is debatable. The load 
dependence of most noninvasive indexes of diastolic filling 
has limited their clinical utility. The lack of consensus 
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regarding the most appropriate ways to quantify and monitor 
changes in diastolic function has greatly limited our ability to 
define the pathophysiology, natural history and impa;t of 
treatment on diastolic dysfunction i  heart failure. 
Pathophysiology 
In the past, hypertension and valvular heart disease were 
the most common etiologic factors associated with heart 
failure. However, as treatments for both of these conditions 
have advanced ramatically, their imponance as causes of 
heart failure has waned. Likewise, the treatment of ischemic 
heart disease has also improved substantial!y in the past 2 
decades and the mortality rate from acute coronary ischemic 
syndromes has decreased markedly during this period. Per- 
haps as a result of these successes, the incidence of heart 
failure and particularly that attributable to ischemic heart 
disease has increased continuously (11.12). Chronic heart fail- 
ure that results from occlusive coronary disease is almost 
invariably associated with both systolic (regional nd global) 
and diastolic dysfunction. 
diated by decreased transcription f the gene encoding this 
protein (15-17). Numerous experimental studies (6) have 
documented prolongation f the decline in the free intracel- 
lular calcium concentrdtion in hypertrophied or failing myo- 
cardium. Of note, left ventricular hypertrophy caused by 
chronic exercise training or hyperthyroidism does not cause 
slow myocardial relaxation. Pathologic left ventricular hy- 
pertrophy may be associated with chronic subendocardial 
isc+emia due to decreased capillary density and blunted 
vasodilator reserve (18-20). This would also be expected to 
impair left ventricular relaxation. Finally. global left ventric- 
ular relaxation may be slowed in the presence of regional 
mechanical asynchrony, such as that seen after segmental 
myocardial infarction (21,22). All of these factors almost 
universally cause impairment of left ventricular relaxation i
a wide variety of cardiac diseases. 
“Pure” diastolic dysfunction with preserved systolic 
function is seen mainly in patients with significant left 
ventricular hypertrophy. Ti..s may be primary, as in hypcr- 
trophic cardiomyopathy, or secondary to other diseases 
such as hypertension r valvular aortic stenosis. Infiltrative 
myocardial disease may cause heart failure due to diastolic 
dysfunction; however, these patients very commonly exhibit 
some contractile impairment by the time symptoms develop. 
Diastolic abnormalities intrinsic to the left ventricle pre- 
dominantly relate to one of three mechanisms. First, slowed 
or incomplete l ft ventricular relaxation is a common abnor- 
mality in many different cardiac diseases. Impaired relax- 
ation aEects early diastolic filling, but may also shift the 
entire left ventricuiar diastolic pressure-volume relation up- 
ward (increased pressure relative to volume throughout 
diastole) and thereby cause congestive symptoms (13,14). 
Second, increased left ventricular wall thickness due to 
myocardial hypertrophy, amyloidosis or other infiltrative 
disorders will tend to increase left ventricular chamber 
stiffness and thereby affect both early and late diastolic 
filling. Finally, accumulation f interstitial collagen, acom- 
mon accompaniment of hypertrophy or infarction, will in- 
crease myocardial stiffness. An increase in the intrinsic 
stiffness of an individual unit of myocardium will contribute 
to elevated chamber stiffness and thereby increase diastolic 
pressure. 
Factors that affect left ventricular chamber st&ess. As 
discussed previously, increased left ventricular wall thick- 
ness relative to cavity size will increase chamber stiffness. 
Typically, conditions associated with chronic pressure over- 
load, such as systemic hypertension rvalvular aortic ste- 
nosis, will cause this type of concentric left ventricular 
hypertrophy. In comparison, conditions associated with 
eccentric hypertrophy, such as chronic volume overload 
states, will tend to decrease chamber stiffness. The de- 
cr-?ased chamber stiffness associated with a dilated ventricle 
may be offset by increases in the intrinsic stiffness ofa given 
unit of myocardium (8). it is commonly believed that in- 
creased myocardial stiffness is related in large part to in- 
creased eposition of collagen in the cardiac interstitium 
(23). It is likely that increasec? myocardial stiffness is a major 
cause of diastolic dysfunction and may be an important 
factor in the transition from compensated left ventricular 
hypertrophy to heart failure (24.25). 
Therapy of Diastolic Dysfunction 
When designing effective strategies for the treatment of
systolic or diastolic heart failare, it is worthwhile toconsider 
the underlying disorder that may be producing or contribut- 
ing to the patient’s symptoms. When ischemia scontribut- 
ing to diastolic dysfunction, improved oxygen delivery may 
alleviate the abnormality. Likewise, when the main abnor- 
malities are extrinsic to the ventricle, such as constrictive 
p&a&is, therapy should be specific for that entity. Un- 
fortunately, at the present time few drugs specifically im- 
prove any of the major aspects of diastolic function. 
Factors that affect left ventricular relaxation. Sarco- There are four primary targets for pharmacologic therapy 
plasmic reticulum calcium uptake is an energy-dependent of intrinsic diastolic dysfunction: 1) decreasing central blood 
process. Hence, any condition associated with decreased volume Lnd thus lowering operating chamber stiffness by 
availability of hiih energy phosphates, such as ischemia or descending to a lower portion of the pressure-volume rela- 
hypoxia, may impair myocardial relaxation (6.7). In addi- tion; 2) enhancing the rate of left ventricular relaxation; 
tion, left ventricular hypertrophy caused by pressure over- 3) decreasing left ventricular wall thickness: and 4) inhibiting 
load is typically accompanied by impaired left ventricular the deposition of or removing excess interstitial COllIlCCtk 
relaxation. This may be related to decreased sarcoplasmic tissue. in addition, a secondary therapeutic goal may be to 
reticular calcium adenosine triphosphatase pump sites me- improve coronary blood flow or limit myocardial ischemia. 
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Methods of achieving this may include: 1) slowing the heart 
rate and thus lengthening the diastolic filling period; 
2) lowering rr;vocamiial oxygen demand; and 3) improving 
coronary vasodilator reserve. The latter three objectives are 
all directed primarily at relieving myocardial ischernia nd 
therefore do not qualify as primary treatment of diastolic 
abnormalities of the left ventricle. 
mering central blood volume. The first target is the 
most readily achieved with today’s drugs. Diuretic agents 
are clearly effective in decreasing blood volume and they 
may lower left ventricular tilling pressures when adminis- 
tered on a short-term or long-term basis. Angiotensin- 
converting enzyme inhibitors may also be effective in this 
regard because they blunt he production ofaldosterone and 
thus decrease the salt and water etention typically associ- 
ated with congestive h art failure. Venodilating a ents uch 
as long-acting nitrates or angiotensin-converting enzyme 
inhibitors may also lower preload by shifting blood into the 
capacitance v ssels (26). There have been few clinical trials 
using diuretic agents alone, although one study (27) found 
that furosemide alone did not prevent pathologic left ven- 
tricular remodeling after myocardial infarction, whereas 
angiotensin-converting enzyme inhibitors did. The ditferent 
responses tothese two classes of drugs may be attributed to
the fact that diuretic therapy may cause neurohumoral 
activation, leading to vasoconstriction a d worsening myo- 
cardii function, whereas angiotensin-converting enzyme 
inhibitors have been shown to decrease some markers of 
neurohumoral activation. Beta-adrenergic blocking agents 
have little direct effect on preload, although they may 
indirectly tiect intravascular volume by inhibiting renin 
formation that is mediated by sympathetic tone. Calcium 
channel blockers and direct vasodilators such as minoxidil 
and hydralazine, although effective arterial dilators, have 
little venodilating capability and thus do little to lower 
preload. The “pure” arterial dilators tend to be associated 
with fluid retention that probably is caused by reflex sympa- 
thetic activation. 
Enhancing the rate af left ventricular relaxation. Several 
available drugs enhance the rate of left ventricular relax- 
ation, a “lusitropic” effect (28). The most prominent ofthese 
are the beta-adrenergic agonists and the phosphodiesterase 
inhibitors. In each case, the lusitropic effect appears to be 
mediated by increasing production or limiting breakdown of
cyclic AMP in the myocyte. Increased cyclic AMP de- 
creases the affinity of troponin C for calcium, in addition to 
stimulating sarcoplasmic reticular calcium uptake. The net 
effect of these changes i a marked enhancement i  he rate 
of left ventricular o myocardial relaxation (Fig. 2). Interest- 
ingly, in failing myocardium, the positive lusitropic effect of 
catecholamines appears to be maintained, even though the 
positive inotropic effect of these drugs is generaliy severely 
blunted (D-31). Although cyclic AMP-dependent agents 
favorably affect he rate of calcium sequestration by the 
~COPhSk retiCUhm, they also Shi!& calcium influx 
into the cell through the sarcolemmal calcium channels and 
hence may increase total intracellular &turn. Continued 
elevations ofcyclic AMP by means of beta-adrenergic st m- 
ulation or phosphodiesterase inhibition may eventually ead 
to cellular calcium overload, arrhythmias nd cell death (Fig. 
2) (31,32). Several trials, mostly short-term, have demon- 
strated enhanced rates of left ventricular relaxation i pa- 
tients with heart failure during treatment with beta-agonists 
(29,3 l-35) and phosphodiesterase inhibitors (36-40). 
Whether these salutary effects ate sustained uring long- 
term treatment is less clear. Unfortunately, the tendency of 
these drugs to cause serious arrhythmias in patients with 
heart failure may limit their utility (41,42). Ultimately, it 
would be desirable to develop agents that can selectively 
augment myocardial relaxation without predisposing to cel- 
lular calcium overload. 
Calcium channel blockers have been suggested aspoten- 
tial agents to improve diastolic relaxation. Several clinical 
studies have found evidence of improved iastolic pressure- 
volume relation atter treatment with calcium channel block- 
ers in patients with heart failure. However, in most cases, 
similar effects were seen with administration f nitroprusside 
(43.44). These findings uggest that he effects of the calcium 
channel blockers are related primarily to their favorable 
effects on left ventricular afterload, rather than to direct 
myocardial effects. Because the vast majority of the free 
cytoplasmic calcium responsible for myofilament activation 
originates from intracellular storage sites in the sarcoplasmir 
reticulum, it is unlikely that sarcolemmal calcium channei 
blockade would have a significant effect on myocardial 
relaxation. Incontrast, in patients with hypertrophic cardio- 
myopathy, there is some evidence to suggest that there are 
increased numbers of sarcolemmal calcium channels, and 
this could directly contribute othe pathophysiology of this 
disorder (45). In addition, it has been demonstrated that 
myocardial tissue from these patients is characterized by
incomplete relaxation and diastolic calcium overload in 
certain situations (46). Thus, there is a more compelling 
rationale for the use of calcium channel blockers in patients 
with this disease. Clinical data showing efficacy of calcium 
channel blockers in achieving symptomatic improvement i  
patients with hypertrophic cardiomyopathy also support 
these theoretic considerations (47). 
IkzreaGig left ventricdar wall thiess. Myocardial hy- 
pertrophy almost certainly plays an adaptive role in allowing 
the injured heart o maintain forward stroke volume (48.49). 
Unfortunately, the increased wall thickness may improve 
systolic function at the expense of impaired iastolic filling. 
Therapy directed toward producing regression of left ven- 
tricular hypertrophy may be beneficial s long as it does not 
cause afterload mismatch. If arterial pressure (aortic imped- 
ance) decreases in proportion to the decrease inleft ventric- 
ular wall mass, wall stress will be maintained. Several agents 
are known to be capable of producing decreases in left 
ventricular mass in patients and experimental animals with 
hypertension. These include: angiotensin-converting e - 
zyme inhibitors, calcium channel blockers, central-acting 
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Figure 2. Examples of isometric 
contraction and inlracellular cal- 
cium transient in left ventricular 
papillary muscles from a normal 
rat (top) and a rat with postinfarc- 
tion heart failure (bottom). The 
papillary muscle from the rat with 
the myocardial infarction (MI) 
was taken from a noninfarcted 
region of the ventricle. Calcium 
transients were recorded with the 
bioluminescent protein aequorin 6 
weeks after sham operation or 
myocardial infarction. Under 
baseline conditions (extracellular 
calcium cc*~nceairS?~n I mmoll 
liter), the ti:rlc c~:rti: of both the 
isometric twitch and zhe calcium 
transient is prolonged in the mus- 
cle from the rat with postinfarc- 
tion heart failure. Administration 
of the beta-adrenergic agonist iso- 
proterenol results in increased 
calcium availability. increased 
force development and enhanced 
relaxation in the normal muscle. 
In contrast, in the failing myocar- 
dium, isoproterenol produces no 
inotropic effect despite a signifi- 
cant increase in calcium availabil- 
ity. At higher doses of isoproter- 
enol, calcium overload is evident 
in the failing myocardium as evi- 
denced by the appearance of af- 
lerglimmers and aftercontractions 
(arrow). These are believed to re- 
sult From spontaneous release of 
calcium from the sarcoplasmic 
reticulum and may correspond to 
delayed afterdepolarizations. 
Adapted, with permission of the 
American Heart Association, 
Inc., from Litwin and Morgan 
(31). 
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sympatholytic agents and beta-blockers. Notably, diuretic 
agents and direct-acting vasodilators have not been associ- 
ated with regression ofleft ventricular hypertrophy. It is not 
clear whether regression of left ventricular hypertrophy is
associated with long-term improvements in !eft ventricular 
diastolic function. The few studies (50.51) that have evalu- 
ated this issue do not distinguish between simple improve- 
ments in left ventricular loading conditions during antihyper- 
tensive the:.::ly and longer-term changes in left ventricular 
geometry. The exact &;uli that cause the myocyte to 
hypertrophy are not well understood. Some investigators 
(52) believe that calcium or cyclic AMP may be important 
second messengers in this process. If this is the case, drugs 
that act by increasing cyclic AMP could actually worsen left 
ventricular hypertrophy, although this possibility has not 
been investigated. 
Regression of inter&M fibrosis. if accumulation f ex- 
traceihdar collagen directly contributes toabnormal diastolic 
function by increasing myocardial stiffness, it should f~!Iow 
that decreasing the amount of connective tissue in the 
interstitial space will improve diastolic function. Altema- 
tively, collagen deposition may only be a marker of myocyte 
injury and ,cell dropout and may not independently contrib- 
ute to left Qentricular dysfunction. Furthermore, it is possi- 
ble that collagen plays an important role in limiting patho- 
logic left ventricular dilation in cases of volume overload 
or myocardial infarction. A growing body of evidence 
(23,25,53,54) supports a primary role for altered extracellular 
matrix in myocardial dysfunction. Unfortunately, there are 
no available drugs that selectively inhibit collagen deposition 
or promote its reabsorption. However, some recent data (23) 
suggest that increased activity of the renin-angiotensin- 
aldosterone system may stimulate the progression of myo- 
cardial fibrosis. In contrast, long-term administration f 
angiotensin-converting enzyme inhibitors or the aldosterone 
antagonist pironolactone may cause regression of intersti- 
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tial collagen (23). Regression of collagen Content seems to 
occur more slowly than regression ofmyocyte hypertrophy 
(23,25). In one study, inhibition of collagen cross-linking 
after imposition ofconstriction ofthe ascending aorta in rats 
was shown to lower est ension in isolated papillary muscles 
without improving contractile performance (54). 
~mprovins myocardii bbod flow. Chronic subendocar- 
dial &hernia at rest, or particularly with exertion, may 
cause impairment of left ventricular relaxation and may 
contribute to cell dropout and replacement fibrosis. Condi- 
tions commonly causing diastolic dysfunction, such as hy- 
pertension ormyocardial infarction, have been shown to be 
associated with abnormalities of endothelial function and 
impaired coronary vasodilator reserve (18-20). Thus, im- 
proving left ventricular blood flow may have beneficial 
effects on left ventricular diastolic function. In addition, 
improved blood flow may augment systolic function in areas 
of hibernating myocardium, aswell as possibly prevent the 
development of interstitial fibrosis. Myocardial ischemia 
may be relieved by improving coronary vasodilator reserve, 
increasing the diastolic filling period or lowering myocardial 
oxygen demand. Vasodilators, nitrates and calcium channel 
blockers all have the potential to improve coronary flow. In 
addition, angiotensin-converting enzyme inhibitors may be 
beneficial in this regard (55). AU of these agents may also 
decrease myocardial oxygen demand by decreasing afterload 
or preload, or both, and thereby lowering left ventricular 
wall stress. Beta-adrenergic blocking agents and some of the 
calcium channel blockers will tend to lower est and exercise 
heart rates. Relative bradycardia should increase the length 
of diastole and hence increase coronary perfusion time. 
Finally, drugs that induce regression of left ventricular 
hypertrophy may also decrease ischemia by decreasing the 
diffusion distance between capillaries inthe myocardium. 
Conclusions. Diastolic dysfunction is an important cause 
of congestive symptoms in patients with heart failure of 
various etiologies. Increased iastolic pressure may result 
from expansion of blood volume, slowed left ventricular 
relaxation, left ventricular hypertrophy and myocardiai ti.
brosis. Various theoretic approaches to each of these prob- 
lems are available. However, at the current time, there are 
few clinical data to substantiate the utility of any therapy 
SpeCtiCaily intended to improve diastolic dysfunction. The 
use of calcium channel blockers and beta-adrenergic ecep- 
tor blockers in the subset of patients with hypertrophic 
cardiomyopathy may be an exception to this generaliza- 
tion. New agents that act specifically on the biochemical 
derangements contributing to diastolic dysfunction at the 
celhdar level. as well as agents that improve l ft ventricular 
geometry, structure and loading conditions, are greatly 
needed. 
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